|
|
|
MIRA INFORM REPORT
|
Report No. : |
493481 |
|
Report Date : |
24.02.2018 |
IDENTIFICATION DETAILS
|
Name : |
C.I. FARMACAPSULAS S.A. |
|
|
|
|
Registered Office : |
Barranquilla |
|
|
|
|
Country : |
Colombia |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
12.05.1975 |
|
|
|
|
Legal Form : |
Sociedad Anonima |
|
|
|
|
Line of Business : |
Manufactures and Supplies Empty Hard Gelatin Capsules. |
|
|
|
|
No. of Employees : |
642 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
Colombia |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
COLOMBIA - ECONOMIC OVERVIEW
Colombia heavily depends on energy and mining exports, making it
vulnerable to fluctuations in commodity prices. Colombia is Latin America’s
fourth largest oil producer and the world’s fourth largest coal producer, third
largest coffee exporter, and second largest cut flowers exporter. Colombia’s
economic development is hampered by inadequate infrastructure, poverty,
narcotrafficking, and an uncertain security situation, in addition to
dependence on primary commodities.
Colombia’s economy slowed in 2017 because of falling global oil prices
and lower oil production due to insurgent attacks on pipeline infrastructure.
Although real GDP growth averaged 4.7% during the past decade, it fell to an
estimated 1.8% in 2017. Declining oil prices also have contributed to reduced
government revenues. In 2016, oil revenue dropped below 4% of the federal
budget and likely remained below 4% in 2017. A Western credit rating agency in
December 2017 downgraded Colombia’s sovereign credit rating to BBB-, because of
weaker-than-expected growth and increasing external debt. Colombia has
struggled to address local referendums against foreign investment, which have
slowed its expansion, especially in the oil and mining sectors. Colombia’s FDI
declined by 3% to $10.2 billion between January and September 2017.
Colombia has signed or is negotiating Free Trade Agreements (FTA) with
more than a dozen countries; the US-Colombia FTA went into effect in May 2012.
Colombia is a founding member of the Pacific Alliance—a regional trade block
formed in 2012 by Chile, Colombia, Mexico, and Peru to promote regional trade
and economic integration. The Colombian government took steps in 2017 to
address several bilateral trade irritants with the US, including those on truck
scrappage, distilled spirits, pharmaceuticals, ethanol imports, and labor
rights. Colombia hopes to accede to the Organization for Economic Cooperation
and Development.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
Legal Name: |
C.I. FARMACAPSULAS S.A. |
|
Trade Name: |
FARMACAPS S.A. |
|
NIT: |
890105927 - 3 |
|
Date Created: |
1975 |
|
Date Incorporated: |
05/12/1975 |
|
Legal Address: |
Barranquilla, Colombia |
|
Operative Address: |
Calle 79 B 78 C 21 Barranquilla, Atlantico, Colombia |
|
Telephone: |
(575) 355-5449 |
|
Fax: |
(575) 330-4197 |
|
Legal Form: |
Sociedad Anonima |
|
Email: |
info@farmacapsulas.com |
|
Registered in: |
COLOMBIA |
|
Website: |
www.farmacapsulas.com |
|
Contact: |
SAUL GILINSKI GROSMAN, General Manager and Agent MAX GILINSKI SRAGOWIEZ, General Manager |
|
Staff: |
642 |
|
Activity: |
Manufacture of pharmaceutical products, medicinal chemicals and
botanical products for pharmaceutical use |
|
|
|
|
Banks: |
The company does not make its banking data public |
|
|
|
|
History: |
C.I. Farmacapsulas S.A. was founded in 1975 and is based in
Barranquilla, Colombia. 1990 Development of Immediate Response Pharmaceutical Forms through
contract manufacturing/Tolling agreement. 1995 The medicine and micro-pellets facility was opened and own
manufacturing of immediate response medicine began. 1996 Followed by the manufacturing of controlled release in pellets form. 1999 Beginning of the production of vegetable capsules 2001 Slose working relationship with our strategic partner in North America
is consolidated : CAPSCANADA, Canada®. in Winsor (ONT) 2002 Capsuline®, the e-commerce channel is created for the distribution of
hard capsules. 2006 Farmacapsulas makes their product more appealing by launching flavored
capsules, which also enhaces the product's user experience. 2009 Beginning of the production of pellets with the use of covering of
fluid bed technology. 2010 Operation and Logistic Center starts operating. 2011 Beginning of production of the filling of hard capsules with liquid
products. 2014 Farmacapsulas begins the vegetable capsules manufacturing in Canada. |
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
|
C.I. Farmacapsulas S.A. manufactures and supplies empty hard gelatin
capsules. |
|
Products/Services description: |
It offers gelatin and vegetable capsules. The company also operates in
contract manufacturing of oral and OTC products in the form of capsules,
tablets, and liquids (solutions and suspensions); modified released pellets;
and liquid-filled hard capsules for pharmaceutical, OTC, and health nutrition
products. |
|
Brands: |
NA |
|
Sales are: |
Wholesale |
|
Clients: |
Nueva Ind. Farmaceutica Asociada S.A., ECUADOR OSMOPHARM USA, USA Innova Andina Sa., PERU |
|
Suppliers: |
AJIX INC., USA Gelita Do Brasil Ltda., BRAZIL |
|
Operations area: |
National and International |
|
The company imports from |
USA, BRAZIL |
|
The company exports to |
ECUADOR, USA, PERU |
|
The subject employs |
642 employees |
|
Payments: |
No Complaints |
|
|
|
LOCATION
|
|
|
Headquarters : |
Calle 79 B 78 C 21 Barranquilla, Atlantico, Colombia |
|
Size: |
NA |
|
Branches: |
No |
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
COP 2000000 |
|
Shareholders: |
This is a private company. We could not confirm any major holder. |
|
Management: |
SAUL GILINSKI GROSMAN, General Manager and Agent MAX GILINSKI SRAGOWIEZ, General Manager |
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
We attach company’s 2016 Financial Stataments |
|
|
|
LEGAL
FILINGS
|
|
|
There are not any legal records connected to the subject. |
|
|
|
|
SUMMARY
|
|
|
|
Founded in 1975, C I Farmacapsulas S A is a large organization in the medicinal
and botanical companies industry located in Barranquilla, Colombia. It is a large-sized company
which has approximately 642 full-time employees. It imports from USA and BRAZIL. In addition, it exports to ECUADOR,
USA and PERU. This is an ACTIVE company incorporated in COLOMBIA since 1975. |
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
No Complaints |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
INTERVIEW |
|
|
NAME |
Diego Valejos |
|
POSITION |
Sales |
|
COMMENTS |
He confirmed name, trade name, RUT, experience, estimated staff and
financial figures. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.82 |
|
|
1 |
INR 90.40 |
|
Euro |
1 |
INR 79.76 |
|
COP |
1 |
INR 0.023 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with moderate
risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on secured
terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.